nodes	percent_of_prediction	percent_of_DWPC	metapath
Nelarabine—Nucleic Acid Synthesis Inhibitors—Capecitabine—colon cancer	0.456	0.515	CiPCiCtD
Nelarabine—Nucleic Acid Synthesis Inhibitors—Fluorouracil—colon cancer	0.429	0.485	CiPCiCtD
Nelarabine—DGUOK—smooth muscle tissue—colon cancer	0.00207	0.0827	CbGeAlD
Nelarabine—DGUOK—renal system—colon cancer	0.00199	0.0796	CbGeAlD
Nelarabine—DGUOK—lymphoid tissue—colon cancer	0.00165	0.0661	CbGeAlD
Nelarabine—DGUOK—digestive system—colon cancer	0.00163	0.0653	CbGeAlD
Nelarabine—DGUOK—bone marrow—colon cancer	0.00151	0.0602	CbGeAlD
Nelarabine—DGUOK—vagina—colon cancer	0.00144	0.0577	CbGeAlD
Nelarabine—DGUOK—liver—colon cancer	0.00122	0.0486	CbGeAlD
Nelarabine—ADA—renal system—colon cancer	0.00114	0.0455	CbGeAlD
Nelarabine—DCK—Topotecan—Irinotecan—colon cancer	0.00111	0.571	CbGdCrCtD
Nelarabine—DCK—embryo—colon cancer	0.001	0.04	CbGeAlD
Nelarabine—ADA—lymphoid tissue—colon cancer	0.000946	0.0378	CbGeAlD
Nelarabine—ADA—digestive system—colon cancer	0.000934	0.0374	CbGeAlD
Nelarabine—DGUOK—lymph node—colon cancer	0.000933	0.0373	CbGeAlD
Nelarabine—POLA1—bone marrow—colon cancer	0.000929	0.0371	CbGeAlD
Nelarabine—POLA1—vagina—colon cancer	0.00089	0.0356	CbGeAlD
Nelarabine—ADA—bone marrow—colon cancer	0.000861	0.0344	CbGeAlD
Nelarabine—POLA1—Vinblastine—Vincristine—colon cancer	0.000836	0.429	CbGdCrCtD
Nelarabine—ADA—vagina—colon cancer	0.000825	0.033	CbGeAlD
Nelarabine—DGUOK—Nucleotide metabolism—TYMS—colon cancer	0.000794	0.0602	CbGpPWpGaD
Nelarabine—POLA1—liver—colon cancer	0.000751	0.03	CbGeAlD
Nelarabine—DCK—lymphoid tissue—colon cancer	0.000629	0.0251	CbGeAlD
Nelarabine—DCK—Pyrimidine metabolism—TYMS—colon cancer	0.000625	0.0473	CbGpPWpGaD
Nelarabine—DCK—digestive system—colon cancer	0.000621	0.0248	CbGeAlD
Nelarabine—POLA1—G1/S-Specific Transcription—TYMS—colon cancer	0.000603	0.0456	CbGpPWpGaD
Nelarabine—POLA1—lymph node—colon cancer	0.000575	0.023	CbGeAlD
Nelarabine—DCK—bone marrow—colon cancer	0.000573	0.0229	CbGeAlD
Nelarabine—DCK—vagina—colon cancer	0.000548	0.0219	CbGeAlD
Nelarabine—ADA—lymph node—colon cancer	0.000534	0.0213	CbGeAlD
Nelarabine—Adenosine triphosphate—AKT1—colon cancer	0.000483	0.463	CrCbGaD
Nelarabine—Adenosine monophosphate—SRC—colon cancer	0.000476	0.456	CrCbGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—MSH6—colon cancer	0.000468	0.0354	CbGpPWpGaD
Nelarabine—DCK—liver—colon cancer	0.000463	0.0185	CbGeAlD
Nelarabine—DGUOK—Metabolism—CA7—colon cancer	0.000459	0.0348	CbGpPWpGaD
Nelarabine—DCK—lymph node—colon cancer	0.000355	0.0142	CbGeAlD
Nelarabine—POLA1—E2F mediated regulation of DNA replication—TYMS—colon cancer	0.000354	0.0268	CbGpPWpGaD
Nelarabine—ADA—Circadian rythm related genes—TOP1—colon cancer	0.000351	0.0266	CbGpPWpGaD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—MSH6—colon cancer	0.000342	0.0259	CbGpPWpGaD
Nelarabine—ADA—Validated transcriptional targets of TAp63 isoforms—BAX—colon cancer	0.000341	0.0258	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—ODC1—colon cancer	0.000278	0.0211	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—CHST5—colon cancer	0.000278	0.0211	CbGpPWpGaD
Nelarabine—ADA—Nucleotide metabolism—TYMS—colon cancer	0.000264	0.02	CbGpPWpGaD
Nelarabine—ADA—p73 transcription factor network—BAX—colon cancer	0.000251	0.019	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—TOP1—colon cancer	0.000247	0.0187	CbGpPWpGaD
Nelarabine—DCK—Nucleotide metabolism—TYMS—colon cancer	0.000243	0.0184	CbGpPWpGaD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—TYMS—colon cancer	0.000223	0.0169	CbGpPWpGaD
Nelarabine—POLA1—E2F transcription factor network—TYMS—colon cancer	0.000188	0.0142	CbGpPWpGaD
Nelarabine—Sepsis—Capecitabine—colon cancer	0.000176	0.0024	CcSEcCtD
Nelarabine—Mental disability—Capecitabine—colon cancer	0.000176	0.0024	CcSEcCtD
Nelarabine—Speech disorder—Methotrexate—colon cancer	0.000176	0.0024	CcSEcCtD
Nelarabine—Pneumonia—Vincristine—colon cancer	0.000175	0.00239	CcSEcCtD
Nelarabine—Depression—Vincristine—colon cancer	0.000174	0.00237	CcSEcCtD
Nelarabine—ADA—Validated transcriptional targets of TAp63 isoforms—CDKN1A—colon cancer	0.000172	0.0131	CbGpPWpGaD
Nelarabine—Neuropathy peripheral—Vincristine—colon cancer	0.000171	0.00233	CcSEcCtD
Nelarabine—Pneumonia—Irinotecan—colon cancer	0.000171	0.00233	CcSEcCtD
Nelarabine—Stomatitis—Vincristine—colon cancer	0.00017	0.00232	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	0.000169	0.0128	CbGpPWpGaD
Nelarabine—Hyperbilirubinaemia—Methotrexate—colon cancer	0.000166	0.00227	CcSEcCtD
Nelarabine—Stomatitis—Irinotecan—colon cancer	0.000166	0.00226	CcSEcCtD
Nelarabine—ADA—Validated transcriptional targets of TAp63 isoforms—EP300—colon cancer	0.000164	0.0124	CbGpPWpGaD
Nelarabine—Pneumonia—Fluorouracil—colon cancer	0.000164	0.00223	CcSEcCtD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—TYMS—colon cancer	0.000163	0.0124	CbGpPWpGaD
Nelarabine—Hyperuricaemia—Methotrexate—colon cancer	0.000163	0.00222	CcSEcCtD
Nelarabine—Infestation NOS—Fluorouracil—colon cancer	0.000163	0.00222	CcSEcCtD
Nelarabine—Infestation—Fluorouracil—colon cancer	0.000163	0.00222	CcSEcCtD
Nelarabine—Dysarthria—Methotrexate—colon cancer	0.00016	0.00218	CcSEcCtD
Nelarabine—Neuropathy peripheral—Fluorouracil—colon cancer	0.000159	0.00217	CcSEcCtD
Nelarabine—Stomatitis—Fluorouracil—colon cancer	0.000159	0.00216	CcSEcCtD
Nelarabine—Amnesia—Capecitabine—colon cancer	0.000157	0.00214	CcSEcCtD
Nelarabine—Hypoaesthesia—Vincristine—colon cancer	0.000156	0.00212	CcSEcCtD
Nelarabine—Urinary tract disorder—Vincristine—colon cancer	0.000155	0.00211	CcSEcCtD
Nelarabine—Blood uric acid increased—Methotrexate—colon cancer	0.000154	0.0021	CcSEcCtD
Nelarabine—Connective tissue disorder—Vincristine—colon cancer	0.000154	0.0021	CcSEcCtD
Nelarabine—Urethral disorder—Vincristine—colon cancer	0.000153	0.00209	CcSEcCtD
Nelarabine—Epistaxis—Fluorouracil—colon cancer	0.000153	0.00209	CcSEcCtD
Nelarabine—Sinusitis—Fluorouracil—colon cancer	0.000153	0.00208	CcSEcCtD
Nelarabine—ADA—Metabolism—CA7—colon cancer	0.000152	0.0115	CbGpPWpGaD
Nelarabine—Lethargy—Capecitabine—colon cancer	0.00015	0.00205	CcSEcCtD
Nelarabine—Connective tissue disorder—Irinotecan—colon cancer	0.00015	0.00204	CcSEcCtD
Nelarabine—Pain in extremity—Capecitabine—colon cancer	0.000147	0.00201	CcSEcCtD
Nelarabine—Osteoarthritis—Capecitabine—colon cancer	0.000147	0.00201	CcSEcCtD
Nelarabine—Depressed level of consciousness—Methotrexate—colon cancer	0.000146	0.00199	CcSEcCtD
Nelarabine—Cardiac disorder—Vincristine—colon cancer	0.000145	0.00198	CcSEcCtD
Nelarabine—Hypoaesthesia—Fluorouracil—colon cancer	0.000145	0.00198	CcSEcCtD
Nelarabine—Angiopathy—Vincristine—colon cancer	0.000142	0.00194	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	0.000142	0.0108	CbGpPWpGaD
Nelarabine—Cardiac disorder—Irinotecan—colon cancer	0.000141	0.00193	CcSEcCtD
Nelarabine—Mediastinal disorder—Vincristine—colon cancer	0.000141	0.00192	CcSEcCtD
Nelarabine—DCK—Metabolism—CA7—colon cancer	0.000141	0.0106	CbGpPWpGaD
Nelarabine—Ataxia—Capecitabine—colon cancer	0.000139	0.00189	CcSEcCtD
Nelarabine—ADA—C-MYB transcription factor network—PTGS2—colon cancer	0.000138	0.0105	CbGpPWpGaD
Nelarabine—Angiopathy—Irinotecan—colon cancer	0.000138	0.00188	CcSEcCtD
Nelarabine—Coma—Methotrexate—colon cancer	0.000138	0.00188	CcSEcCtD
Nelarabine—Blood creatinine increased—Capecitabine—colon cancer	0.000138	0.00188	CcSEcCtD
Nelarabine—Mediastinal disorder—Irinotecan—colon cancer	0.000137	0.00187	CcSEcCtD
Nelarabine—Dehydration—Capecitabine—colon cancer	0.000137	0.00187	CcSEcCtD
Nelarabine—Mental disorder—Vincristine—colon cancer	0.000137	0.00187	CcSEcCtD
Nelarabine—Chills—Irinotecan—colon cancer	0.000137	0.00186	CcSEcCtD
Nelarabine—Neoplasm—Methotrexate—colon cancer	0.000137	0.00186	CcSEcCtD
Nelarabine—POLA1—G1/S Transition—TYMS—colon cancer	0.000136	0.0103	CbGpPWpGaD
Nelarabine—Hypokalaemia—Capecitabine—colon cancer	0.000134	0.00183	CcSEcCtD
Nelarabine—Aspartate aminotransferase increased—Capecitabine—colon cancer	0.000133	0.00181	CcSEcCtD
Nelarabine—Back pain—Vincristine—colon cancer	0.000132	0.0018	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—MLH3—colon cancer	0.000131	0.00994	CbGpPWpGaD
Nelarabine—Sepsis—Methotrexate—colon cancer	0.000131	0.00179	CcSEcCtD
Nelarabine—Muscular weakness—Capecitabine—colon cancer	0.00013	0.00177	CcSEcCtD
Nelarabine—Back pain—Irinotecan—colon cancer	0.000128	0.00175	CcSEcCtD
Nelarabine—Abdominal distension—Capecitabine—colon cancer	0.000128	0.00175	CcSEcCtD
Nelarabine—ADA—p73 transcription factor network—CDKN1A—colon cancer	0.000127	0.00963	CbGpPWpGaD
Nelarabine—Anaemia—Vincristine—colon cancer	0.000126	0.00172	CcSEcCtD
Nelarabine—ADA—C-MYB transcription factor network—CCND1—colon cancer	0.000125	0.00948	CbGpPWpGaD
Nelarabine—ADA—Circadian rythm related genes—TYMS—colon cancer	0.000124	0.00937	CbGpPWpGaD
Nelarabine—Anaemia—Irinotecan—colon cancer	0.000123	0.00167	CcSEcCtD
Nelarabine—Leukopenia—Vincristine—colon cancer	0.000122	0.00166	CcSEcCtD
Nelarabine—ADA—C-MYB transcription factor network—CDKN1A—colon cancer	0.000121	0.00917	CbGpPWpGaD
Nelarabine—ADA—p73 transcription factor network—EP300—colon cancer	0.000121	0.00916	CbGpPWpGaD
Nelarabine—Vision blurred—Fluorouracil—colon cancer	0.00012	0.00163	CcSEcCtD
Nelarabine—Neutropenia—Capecitabine—colon cancer	0.000119	0.00162	CcSEcCtD
Nelarabine—Leukopenia—Irinotecan—colon cancer	0.000119	0.00162	CcSEcCtD
Nelarabine—Convulsion—Vincristine—colon cancer	0.000118	0.00161	CcSEcCtD
Nelarabine—Anaemia—Fluorouracil—colon cancer	0.000117	0.0016	CcSEcCtD
Nelarabine—Loss of consciousness—Irinotecan—colon cancer	0.000117	0.00159	CcSEcCtD
Nelarabine—Myalgia—Vincristine—colon cancer	0.000116	0.00158	CcSEcCtD
Nelarabine—Cough—Irinotecan—colon cancer	0.000116	0.00158	CcSEcCtD
Nelarabine—ADA—C-MYB transcription factor network—EP300—colon cancer	0.000115	0.00872	CbGpPWpGaD
Nelarabine—Hyperglycaemia—Capecitabine—colon cancer	0.000115	0.00157	CcSEcCtD
Nelarabine—POLA1—Mitotic G1-G1/S phases—TYMS—colon cancer	0.000115	0.0087	CbGpPWpGaD
Nelarabine—Pneumonia—Capecitabine—colon cancer	0.000114	0.00156	CcSEcCtD
Nelarabine—Leukopenia—Fluorouracil—colon cancer	0.000114	0.00155	CcSEcCtD
Nelarabine—Infestation NOS—Capecitabine—colon cancer	0.000114	0.00155	CcSEcCtD
Nelarabine—Infestation—Capecitabine—colon cancer	0.000114	0.00155	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	0.000113	0.0086	CbGpPWpGaD
Nelarabine—Depression—Capecitabine—colon cancer	0.000113	0.00154	CcSEcCtD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—CCND1—colon cancer	0.000112	0.0085	CbGpPWpGaD
Nelarabine—Lethargy—Methotrexate—colon cancer	0.000112	0.00153	CcSEcCtD
Nelarabine—Neuropathy peripheral—Capecitabine—colon cancer	0.000111	0.00152	CcSEcCtD
Nelarabine—Oedema—Vincristine—colon cancer	0.000111	0.00152	CcSEcCtD
Nelarabine—Stomatitis—Capecitabine—colon cancer	0.000111	0.00151	CcSEcCtD
Nelarabine—Infection—Vincristine—colon cancer	0.00011	0.00151	CcSEcCtD
Nelarabine—Convulsion—Fluorouracil—colon cancer	0.00011	0.0015	CcSEcCtD
Nelarabine—Osteoarthritis—Methotrexate—colon cancer	0.00011	0.0015	CcSEcCtD
Nelarabine—Confusional state—Irinotecan—colon cancer	0.000109	0.00149	CcSEcCtD
Nelarabine—Nervous system disorder—Vincristine—colon cancer	0.000109	0.00149	CcSEcCtD
Nelarabine—Thrombocytopenia—Vincristine—colon cancer	0.000109	0.00148	CcSEcCtD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—CDKN1A—colon cancer	0.000109	0.00823	CbGpPWpGaD
Nelarabine—Oedema—Irinotecan—colon cancer	0.000108	0.00148	CcSEcCtD
Nelarabine—Chest pain—Fluorouracil—colon cancer	0.000108	0.00147	CcSEcCtD
Nelarabine—Myalgia—Fluorouracil—colon cancer	0.000108	0.00147	CcSEcCtD
Nelarabine—ADA—C-MYB transcription factor network—NRAS—colon cancer	0.000108	0.00816	CbGpPWpGaD
Nelarabine—Infection—Irinotecan—colon cancer	0.000108	0.00147	CcSEcCtD
Nelarabine—Hepatobiliary disease—Capecitabine—colon cancer	0.000107	0.00146	CcSEcCtD
Nelarabine—Epistaxis—Capecitabine—colon cancer	0.000107	0.00146	CcSEcCtD
Nelarabine—Nervous system disorder—Irinotecan—colon cancer	0.000106	0.00145	CcSEcCtD
Nelarabine—Thrombocytopenia—Irinotecan—colon cancer	0.000106	0.00144	CcSEcCtD
Nelarabine—Anorexia—Vincristine—colon cancer	0.000106	0.00144	CcSEcCtD
Nelarabine—ADA—p73 transcription factor network—MYC—colon cancer	0.000105	0.00798	CbGpPWpGaD
Nelarabine—Confusional state—Fluorouracil—colon cancer	0.000105	0.00143	CcSEcCtD
Nelarabine—Hypotension—Vincristine—colon cancer	0.000104	0.00142	CcSEcCtD
Nelarabine—Oedema—Fluorouracil—colon cancer	0.000104	0.00141	CcSEcCtD
Nelarabine—Anorexia—Irinotecan—colon cancer	0.000103	0.00141	CcSEcCtD
Nelarabine—Ataxia—Methotrexate—colon cancer	0.000103	0.00141	CcSEcCtD
Nelarabine—Infection—Fluorouracil—colon cancer	0.000103	0.0014	CcSEcCtD
Nelarabine—Nervous system disorder—Fluorouracil—colon cancer	0.000102	0.00139	CcSEcCtD
Nelarabine—Thrombocytopenia—Fluorouracil—colon cancer	0.000102	0.00138	CcSEcCtD
Nelarabine—Hypoaesthesia—Capecitabine—colon cancer	0.000102	0.00138	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Vincristine—colon cancer	0.000101	0.00138	CcSEcCtD
Nelarabine—Hypotension—Irinotecan—colon cancer	0.000101	0.00138	CcSEcCtD
Nelarabine—Urinary tract disorder—Capecitabine—colon cancer	0.000101	0.00137	CcSEcCtD
Nelarabine—Insomnia—Vincristine—colon cancer	0.000101	0.00137	CcSEcCtD
Nelarabine—Oedema peripheral—Capecitabine—colon cancer	0.000101	0.00137	CcSEcCtD
Nelarabine—ADA—C-MYB transcription factor network—MYC—colon cancer	0.0001	0.0076	CbGpPWpGaD
Nelarabine—Connective tissue disorder—Capecitabine—colon cancer	0.0001	0.00137	CcSEcCtD
Nelarabine—Urethral disorder—Capecitabine—colon cancer	0.0001	0.00136	CcSEcCtD
Nelarabine—Paraesthesia—Vincristine—colon cancer	9.99e-05	0.00136	CcSEcCtD
Nelarabine—Anorexia—Fluorouracil—colon cancer	9.89e-05	0.00135	CcSEcCtD
Nelarabine—Insomnia—Irinotecan—colon cancer	9.79e-05	0.00133	CcSEcCtD
Nelarabine—Paraesthesia—Irinotecan—colon cancer	9.72e-05	0.00133	CcSEcCtD
Nelarabine—Hypotension—Fluorouracil—colon cancer	9.69e-05	0.00132	CcSEcCtD
Nelarabine—Decreased appetite—Vincristine—colon cancer	9.67e-05	0.00132	CcSEcCtD
Nelarabine—Dyspnoea—Irinotecan—colon cancer	9.65e-05	0.00132	CcSEcCtD
Nelarabine—Somnolence—Irinotecan—colon cancer	9.63e-05	0.00131	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Vincristine—colon cancer	9.6e-05	0.00131	CcSEcCtD
Nelarabine—Fatigue—Vincristine—colon cancer	9.59e-05	0.00131	CcSEcCtD
Nelarabine—Eye disorder—Capecitabine—colon cancer	9.53e-05	0.0013	CcSEcCtD
Nelarabine—Constipation—Vincristine—colon cancer	9.51e-05	0.0013	CcSEcCtD
Nelarabine—Pain—Vincristine—colon cancer	9.51e-05	0.0013	CcSEcCtD
Nelarabine—Cardiac disorder—Capecitabine—colon cancer	9.47e-05	0.00129	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Fluorouracil—colon cancer	9.45e-05	0.00129	CcSEcCtD
Nelarabine—Decreased appetite—Irinotecan—colon cancer	9.41e-05	0.00128	CcSEcCtD
Nelarabine—Insomnia—Fluorouracil—colon cancer	9.38e-05	0.00128	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Irinotecan—colon cancer	9.35e-05	0.00127	CcSEcCtD
Nelarabine—Fatigue—Irinotecan—colon cancer	9.34e-05	0.00127	CcSEcCtD
Nelarabine—Paraesthesia—Fluorouracil—colon cancer	9.31e-05	0.00127	CcSEcCtD
Nelarabine—ADA—C-MYB transcription factor network—KRAS—colon cancer	9.27e-05	0.00702	CbGpPWpGaD
Nelarabine—Constipation—Irinotecan—colon cancer	9.26e-05	0.00126	CcSEcCtD
Nelarabine—Pain—Irinotecan—colon cancer	9.26e-05	0.00126	CcSEcCtD
Nelarabine—Angiopathy—Capecitabine—colon cancer	9.26e-05	0.00126	CcSEcCtD
Nelarabine—Dyspnoea—Fluorouracil—colon cancer	9.25e-05	0.00126	CcSEcCtD
Nelarabine—ADA—Metabolism—ODC1—colon cancer	9.23e-05	0.00699	CbGpPWpGaD
Nelarabine—ADA—Metabolism—CHST5—colon cancer	9.23e-05	0.00699	CbGpPWpGaD
Nelarabine—Somnolence—Fluorouracil—colon cancer	9.22e-05	0.00126	CcSEcCtD
Nelarabine—Mediastinal disorder—Capecitabine—colon cancer	9.19e-05	0.00125	CcSEcCtD
Nelarabine—Chills—Capecitabine—colon cancer	9.15e-05	0.00125	CcSEcCtD
Nelarabine—POLA1—E2F transcription factor network—CDKN1A—colon cancer	9.15e-05	0.00693	CbGpPWpGaD
Nelarabine—Gastrointestinal pain—Vincristine—colon cancer	9.09e-05	0.00124	CcSEcCtD
Nelarabine—Decreased appetite—Fluorouracil—colon cancer	9.02e-05	0.00123	CcSEcCtD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—MYC—colon cancer	9.01e-05	0.00682	CbGpPWpGaD
Nelarabine—Gastrointestinal disorder—Fluorouracil—colon cancer	8.95e-05	0.00122	CcSEcCtD
Nelarabine—Mental disorder—Capecitabine—colon cancer	8.94e-05	0.00122	CcSEcCtD
Nelarabine—Feeling abnormal—Irinotecan—colon cancer	8.92e-05	0.00122	CcSEcCtD
Nelarabine—Malnutrition—Capecitabine—colon cancer	8.88e-05	0.00121	CcSEcCtD
Nelarabine—Neutropenia—Methotrexate—colon cancer	8.87e-05	0.00121	CcSEcCtD
Nelarabine—Pain—Fluorouracil—colon cancer	8.87e-05	0.00121	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	8.86e-05	0.00671	CbGpPWpGaD
Nelarabine—Gastrointestinal pain—Irinotecan—colon cancer	8.86e-05	0.00121	CcSEcCtD
Nelarabine—Abdominal pain—Vincristine—colon cancer	8.79e-05	0.0012	CcSEcCtD
Nelarabine—Body temperature increased—Vincristine—colon cancer	8.79e-05	0.0012	CcSEcCtD
Nelarabine—ADA—Circadian rythm related genes—PPARG—colon cancer	8.76e-05	0.00664	CbGpPWpGaD
Nelarabine—POLA1—E2F transcription factor network—EP300—colon cancer	8.71e-05	0.00659	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	8.7e-05	0.00659	CbGpPWpGaD
Nelarabine—Dysgeusia—Capecitabine—colon cancer	8.7e-05	0.00119	CcSEcCtD
Nelarabine—Back pain—Capecitabine—colon cancer	8.59e-05	0.00117	CcSEcCtD
Nelarabine—Abdominal pain—Irinotecan—colon cancer	8.56e-05	0.00117	CcSEcCtD
Nelarabine—Body temperature increased—Irinotecan—colon cancer	8.56e-05	0.00117	CcSEcCtD
Nelarabine—Feeling abnormal—Fluorouracil—colon cancer	8.55e-05	0.00116	CcSEcCtD
Nelarabine—DCK—Metabolism—CHST5—colon cancer	8.52e-05	0.00645	CbGpPWpGaD
Nelarabine—DCK—Metabolism—ODC1—colon cancer	8.52e-05	0.00645	CbGpPWpGaD
Nelarabine—Pneumonia—Methotrexate—colon cancer	8.51e-05	0.00116	CcSEcCtD
Nelarabine—Infestation NOS—Methotrexate—colon cancer	8.46e-05	0.00115	CcSEcCtD
Nelarabine—Infestation—Methotrexate—colon cancer	8.46e-05	0.00115	CcSEcCtD
Nelarabine—Adenosine triphosphate—ABCB1—colon cancer	8.44e-05	0.0808	CrCbGaD
Nelarabine—Depression—Methotrexate—colon cancer	8.44e-05	0.00115	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	8.38e-05	0.00635	CbGpPWpGaD
Nelarabine—Vision blurred—Capecitabine—colon cancer	8.37e-05	0.00114	CcSEcCtD
Nelarabine—Tremor—Capecitabine—colon cancer	8.32e-05	0.00113	CcSEcCtD
Nelarabine—Stomatitis—Methotrexate—colon cancer	8.25e-05	0.00112	CcSEcCtD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—CCND1—colon cancer	8.22e-05	0.00622	CbGpPWpGaD
Nelarabine—Anaemia—Capecitabine—colon cancer	8.21e-05	0.00112	CcSEcCtD
Nelarabine—Body temperature increased—Fluorouracil—colon cancer	8.2e-05	0.00112	CcSEcCtD
Nelarabine—Hepatobiliary disease—Methotrexate—colon cancer	8e-05	0.00109	CcSEcCtD
Nelarabine—Epistaxis—Methotrexate—colon cancer	7.98e-05	0.00109	CcSEcCtD
Nelarabine—Asthenia—Vincristine—colon cancer	7.98e-05	0.00109	CcSEcCtD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—CDKN1A—colon cancer	7.95e-05	0.00602	CbGpPWpGaD
Nelarabine—Leukopenia—Capecitabine—colon cancer	7.95e-05	0.00108	CcSEcCtD
Nelarabine—ADA—C-MYB transcription factor network—HRAS—colon cancer	7.88e-05	0.00597	CbGpPWpGaD
Nelarabine—Loss of consciousness—Capecitabine—colon cancer	7.81e-05	0.00106	CcSEcCtD
Nelarabine—Asthenia—Irinotecan—colon cancer	7.77e-05	0.00106	CcSEcCtD
Nelarabine—Cough—Capecitabine—colon cancer	7.75e-05	0.00106	CcSEcCtD
Nelarabine—Diarrhoea—Vincristine—colon cancer	7.61e-05	0.00104	CcSEcCtD
Nelarabine—POLA1—E2F transcription factor network—MYC—colon cancer	7.59e-05	0.00575	CbGpPWpGaD
Nelarabine—Arthralgia—Capecitabine—colon cancer	7.56e-05	0.00103	CcSEcCtD
Nelarabine—Chest pain—Capecitabine—colon cancer	7.56e-05	0.00103	CcSEcCtD
Nelarabine—Myalgia—Capecitabine—colon cancer	7.56e-05	0.00103	CcSEcCtD
Nelarabine—Urinary tract disorder—Methotrexate—colon cancer	7.5e-05	0.00102	CcSEcCtD
Nelarabine—Urethral disorder—Methotrexate—colon cancer	7.44e-05	0.00101	CcSEcCtD
Nelarabine—Diarrhoea—Irinotecan—colon cancer	7.41e-05	0.00101	CcSEcCtD
Nelarabine—DCK—Retinoblastoma (RB) in Cancer—TP53—colon cancer	7.4e-05	0.0056	CbGpPWpGaD
Nelarabine—Dizziness—Vincristine—colon cancer	7.35e-05	0.001	CcSEcCtD
Nelarabine—POLA1—Synthesis of DNA—CDKN1A—colon cancer	7.35e-05	0.00557	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—ABCB1—colon cancer	7.35e-05	0.00557	CbGpPWpGaD
Nelarabine—POLA1—Mitotic M-M/G1 phases—BUB1B—colon cancer	7.35e-05	0.00556	CbGpPWpGaD
Nelarabine—Confusional state—Capecitabine—colon cancer	7.31e-05	0.000996	CcSEcCtD
Nelarabine—Oedema—Capecitabine—colon cancer	7.25e-05	0.000988	CcSEcCtD
Nelarabine—DGUOK—Metabolism—TYMS—colon cancer	7.22e-05	0.00547	CbGpPWpGaD
Nelarabine—Infection—Capecitabine—colon cancer	7.2e-05	0.000981	CcSEcCtD
Nelarabine—Dizziness—Irinotecan—colon cancer	7.16e-05	0.000976	CcSEcCtD
Nelarabine—Nervous system disorder—Capecitabine—colon cancer	7.11e-05	0.000969	CcSEcCtD
Nelarabine—Eye disorder—Methotrexate—colon cancer	7.1e-05	0.000967	CcSEcCtD
Nelarabine—Diarrhoea—Fluorouracil—colon cancer	7.1e-05	0.000967	CcSEcCtD
Nelarabine—Thrombocytopenia—Capecitabine—colon cancer	7.1e-05	0.000967	CcSEcCtD
Nelarabine—Vomiting—Vincristine—colon cancer	7.07e-05	0.000964	CcSEcCtD
Nelarabine—Cardiac disorder—Methotrexate—colon cancer	7.05e-05	0.000961	CcSEcCtD
Nelarabine—Headache—Vincristine—colon cancer	6.97e-05	0.000949	CcSEcCtD
Nelarabine—Anorexia—Capecitabine—colon cancer	6.91e-05	0.000942	CcSEcCtD
Nelarabine—POLA1—DNA Replication—CDKN1A—colon cancer	6.89e-05	0.00522	CbGpPWpGaD
Nelarabine—Angiopathy—Methotrexate—colon cancer	6.89e-05	0.000939	CcSEcCtD
Nelarabine—Vomiting—Irinotecan—colon cancer	6.89e-05	0.000938	CcSEcCtD
Nelarabine—Dizziness—Fluorouracil—colon cancer	6.86e-05	0.000935	CcSEcCtD
Nelarabine—Mediastinal disorder—Methotrexate—colon cancer	6.84e-05	0.000933	CcSEcCtD
Nelarabine—Chills—Methotrexate—colon cancer	6.81e-05	0.000929	CcSEcCtD
Nelarabine—Headache—Irinotecan—colon cancer	6.78e-05	0.000925	CcSEcCtD
Nelarabine—Hypotension—Capecitabine—colon cancer	6.77e-05	0.000923	CcSEcCtD
Nelarabine—Mental disorder—Methotrexate—colon cancer	6.65e-05	0.000907	CcSEcCtD
Nelarabine—POLA1—G1/S Transition—CDKN1A—colon cancer	6.64e-05	0.00503	CbGpPWpGaD
Nelarabine—Malnutrition—Methotrexate—colon cancer	6.61e-05	0.000901	CcSEcCtD
Nelarabine—Nausea—Vincristine—colon cancer	6.61e-05	0.0009	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Capecitabine—colon cancer	6.6e-05	0.0009	CcSEcCtD
Nelarabine—Vomiting—Fluorouracil—colon cancer	6.59e-05	0.000899	CcSEcCtD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—MYC—colon cancer	6.59e-05	0.00499	CbGpPWpGaD
Nelarabine—Insomnia—Capecitabine—colon cancer	6.56e-05	0.000893	CcSEcCtD
Nelarabine—Paraesthesia—Capecitabine—colon cancer	6.51e-05	0.000887	CcSEcCtD
Nelarabine—Headache—Fluorouracil—colon cancer	6.5e-05	0.000885	CcSEcCtD
Nelarabine—Dysgeusia—Methotrexate—colon cancer	6.47e-05	0.000882	CcSEcCtD
Nelarabine—Dyspnoea—Capecitabine—colon cancer	6.46e-05	0.000881	CcSEcCtD
Nelarabine—Nausea—Irinotecan—colon cancer	6.43e-05	0.000877	CcSEcCtD
Nelarabine—Back pain—Methotrexate—colon cancer	6.39e-05	0.000871	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—APC—colon cancer	6.39e-05	0.00484	CbGpPWpGaD
Nelarabine—Decreased appetite—Capecitabine—colon cancer	6.3e-05	0.000859	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Capecitabine—colon cancer	6.26e-05	0.000853	CcSEcCtD
Nelarabine—Fatigue—Capecitabine—colon cancer	6.25e-05	0.000852	CcSEcCtD
Nelarabine—Vision blurred—Methotrexate—colon cancer	6.23e-05	0.000849	CcSEcCtD
Nelarabine—POLA1—S Phase—CCND1—colon cancer	6.23e-05	0.00472	CbGpPWpGaD
Nelarabine—Pain—Capecitabine—colon cancer	6.2e-05	0.000845	CcSEcCtD
Nelarabine—Constipation—Capecitabine—colon cancer	6.2e-05	0.000845	CcSEcCtD
Nelarabine—Nausea—Fluorouracil—colon cancer	6.16e-05	0.00084	CcSEcCtD
Nelarabine—Anaemia—Methotrexate—colon cancer	6.11e-05	0.000833	CcSEcCtD
Nelarabine—POLA1—S Phase—CDKN1A—colon cancer	6.03e-05	0.00456	CbGpPWpGaD
Nelarabine—Feeling abnormal—Capecitabine—colon cancer	5.97e-05	0.000814	CcSEcCtD
Nelarabine—Gastrointestinal pain—Capecitabine—colon cancer	5.93e-05	0.000808	CcSEcCtD
Nelarabine—Leukopenia—Methotrexate—colon cancer	5.92e-05	0.000806	CcSEcCtD
Nelarabine—POLA1—Mitotic G1-G1/S phases—CCND1—colon cancer	5.78e-05	0.00438	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—MLH1—colon cancer	5.78e-05	0.00438	CbGpPWpGaD
Nelarabine—Cough—Methotrexate—colon cancer	5.77e-05	0.000786	CcSEcCtD
Nelarabine—ADA—Circadian rythm related genes—EP300—colon cancer	5.73e-05	0.00434	CbGpPWpGaD
Nelarabine—Body temperature increased—Capecitabine—colon cancer	5.73e-05	0.000781	CcSEcCtD
Nelarabine—Abdominal pain—Capecitabine—colon cancer	5.73e-05	0.000781	CcSEcCtD
Nelarabine—Convulsion—Methotrexate—colon cancer	5.73e-05	0.000781	CcSEcCtD
Nelarabine—Arthralgia—Methotrexate—colon cancer	5.63e-05	0.000767	CcSEcCtD
Nelarabine—Myalgia—Methotrexate—colon cancer	5.63e-05	0.000767	CcSEcCtD
Nelarabine—Chest pain—Methotrexate—colon cancer	5.63e-05	0.000767	CcSEcCtD
Nelarabine—POLA1—Mitotic G1-G1/S phases—CDKN1A—colon cancer	5.59e-05	0.00424	CbGpPWpGaD
Nelarabine—POLA1—G1/S Transition—MYC—colon cancer	5.5e-05	0.00417	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—BUB1B—colon cancer	5.49e-05	0.00416	CbGpPWpGaD
Nelarabine—Confusional state—Methotrexate—colon cancer	5.44e-05	0.000741	CcSEcCtD
Nelarabine—POLA1—Retinoblastoma (RB) in Cancer—TP53—colon cancer	5.41e-05	0.0041	CbGpPWpGaD
Nelarabine—Infection—Methotrexate—colon cancer	5.36e-05	0.00073	CcSEcCtD
Nelarabine—Nervous system disorder—Methotrexate—colon cancer	5.29e-05	0.000721	CcSEcCtD
Nelarabine—Thrombocytopenia—Methotrexate—colon cancer	5.28e-05	0.00072	CcSEcCtD
Nelarabine—Asthenia—Capecitabine—colon cancer	5.2e-05	0.000709	CcSEcCtD
Nelarabine—Anorexia—Methotrexate—colon cancer	5.14e-05	0.000701	CcSEcCtD
Nelarabine—DGUOK—Metabolism—PPARG—colon cancer	5.11e-05	0.00387	CbGpPWpGaD
Nelarabine—Hypotension—Methotrexate—colon cancer	5.04e-05	0.000687	CcSEcCtD
Nelarabine—POLA1—S Phase—MYC—colon cancer	5e-05	0.00378	CbGpPWpGaD
Nelarabine—Diarrhoea—Capecitabine—colon cancer	4.96e-05	0.000676	CcSEcCtD
Nelarabine—Musculoskeletal discomfort—Methotrexate—colon cancer	4.92e-05	0.00067	CcSEcCtD
Nelarabine—POLA1—Cell Cycle—BUB1B—colon cancer	4.91e-05	0.00372	CbGpPWpGaD
Nelarabine—Insomnia—Methotrexate—colon cancer	4.88e-05	0.000665	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	4.85e-05	0.00367	CbGpPWpGaD
Nelarabine—Paraesthesia—Methotrexate—colon cancer	4.84e-05	0.00066	CcSEcCtD
Nelarabine—Dyspnoea—Methotrexate—colon cancer	4.81e-05	0.000656	CcSEcCtD
Nelarabine—Somnolence—Methotrexate—colon cancer	4.8e-05	0.000654	CcSEcCtD
Nelarabine—Dizziness—Capecitabine—colon cancer	4.79e-05	0.000653	CcSEcCtD
Nelarabine—Decreased appetite—Methotrexate—colon cancer	4.69e-05	0.000639	CcSEcCtD
Nelarabine—Gastrointestinal disorder—Methotrexate—colon cancer	4.66e-05	0.000635	CcSEcCtD
Nelarabine—Fatigue—Methotrexate—colon cancer	4.65e-05	0.000634	CcSEcCtD
Nelarabine—POLA1—Mitotic G1-G1/S phases—MYC—colon cancer	4.64e-05	0.00351	CbGpPWpGaD
Nelarabine—Pain—Methotrexate—colon cancer	4.61e-05	0.000629	CcSEcCtD
Nelarabine—Vomiting—Capecitabine—colon cancer	4.61e-05	0.000628	CcSEcCtD
Nelarabine—Headache—Capecitabine—colon cancer	4.54e-05	0.000619	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	4.5e-05	0.00341	CbGpPWpGaD
Nelarabine—Feeling abnormal—Methotrexate—colon cancer	4.45e-05	0.000606	CcSEcCtD
Nelarabine—Gastrointestinal pain—Methotrexate—colon cancer	4.41e-05	0.000601	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	4.38e-05	0.00332	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	4.34e-05	0.00329	CbGpPWpGaD
Nelarabine—Nausea—Capecitabine—colon cancer	4.31e-05	0.000587	CcSEcCtD
Nelarabine—Abdominal pain—Methotrexate—colon cancer	4.27e-05	0.000581	CcSEcCtD
Nelarabine—Body temperature increased—Methotrexate—colon cancer	4.27e-05	0.000581	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	4.24e-05	0.00321	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—TYMS—colon cancer	4.21e-05	0.00319	CbGpPWpGaD
Nelarabine—ADA—Circadian rythm related genes—TP53—colon cancer	4.1e-05	0.00311	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	4.03e-05	0.00305	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—PTGS2—colon cancer	4.02e-05	0.00305	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	3.92e-05	0.00297	CbGpPWpGaD
Nelarabine—Asthenia—Methotrexate—colon cancer	3.87e-05	0.000528	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	3.82e-05	0.00289	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—TYMS—colon cancer	3.77e-05	0.00285	CbGpPWpGaD
Nelarabine—Diarrhoea—Methotrexate—colon cancer	3.69e-05	0.000503	CcSEcCtD
Nelarabine—Dizziness—Methotrexate—colon cancer	3.57e-05	0.000486	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	3.51e-05	0.00266	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	3.51e-05	0.00266	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	3.44e-05	0.0026	CbGpPWpGaD
Nelarabine—Vomiting—Methotrexate—colon cancer	3.43e-05	0.000468	CcSEcCtD
Nelarabine—Headache—Methotrexate—colon cancer	3.38e-05	0.000461	CcSEcCtD
Nelarabine—DGUOK—Metabolism—EP300—colon cancer	3.34e-05	0.00253	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	3.25e-05	0.00246	CbGpPWpGaD
Nelarabine—Nausea—Methotrexate—colon cancer	3.2e-05	0.000437	CcSEcCtD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	2.98e-05	0.00226	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	2.89e-05	0.00219	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—PIK3CA—colon cancer	2.47e-05	0.00187	CbGpPWpGaD
Nelarabine—ADA—Metabolism—ABCB1—colon cancer	2.44e-05	0.00185	CbGpPWpGaD
Nelarabine—POLA1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	2.44e-05	0.00185	CbGpPWpGaD
Nelarabine—ADA—Metabolism—TYMS—colon cancer	2.4e-05	0.00181	CbGpPWpGaD
Nelarabine—DCK—Metabolism—ABCB1—colon cancer	2.25e-05	0.0017	CbGpPWpGaD
Nelarabine—DCK—Metabolism—TYMS—colon cancer	2.21e-05	0.00167	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—CCND1—colon cancer	2.12e-05	0.00161	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—CDKN1A—colon cancer	2.05e-05	0.00155	CbGpPWpGaD
Nelarabine—DGUOK—Metabolism—AKT1—colon cancer	2.02e-05	0.00153	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—EP300—colon cancer	1.95e-05	0.00148	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—CCND1—colon cancer	1.9e-05	0.00144	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—CDKN1A—colon cancer	1.83e-05	0.00139	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—EP300—colon cancer	1.75e-05	0.00132	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle, Mitotic—MYC—colon cancer	1.7e-05	0.00129	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PPARG—colon cancer	1.7e-05	0.00129	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PPARG—colon cancer	1.57e-05	0.00119	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—MYC—colon cancer	1.52e-05	0.00115	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PTGS2—colon cancer	1.33e-05	0.00101	CbGpPWpGaD
Nelarabine—POLA1—Cell Cycle—TP53—colon cancer	1.25e-05	0.000946	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PTGS2—colon cancer	1.23e-05	0.000933	CbGpPWpGaD
Nelarabine—ADA—Metabolism—EP300—colon cancer	1.11e-05	0.000841	CbGpPWpGaD
Nelarabine—DCK—Metabolism—EP300—colon cancer	1.02e-05	0.000776	CbGpPWpGaD
Nelarabine—ADA—Metabolism—PIK3CA—colon cancer	8.21e-06	0.000622	CbGpPWpGaD
Nelarabine—DCK—Metabolism—PIK3CA—colon cancer	7.58e-06	0.000574	CbGpPWpGaD
Nelarabine—ADA—Metabolism—AKT1—colon cancer	6.71e-06	0.000508	CbGpPWpGaD
Nelarabine—DCK—Metabolism—AKT1—colon cancer	6.19e-06	0.000469	CbGpPWpGaD
